Disease · MONDO_0007606
fibrodysplasia ossificans progressiva
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. fibrodysplasia ossificans progressiva. Diseases, record MONDO_0007606. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007606
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PALOVAROTENE | CHEMBL2105648 | Small molecule | Approval | FDA and TTD | 6 | 3 | 3 | Drugs and targets |
| GARETOSMAB | CHEMBL4298176 | Antibody | Phase 3 | ClinicalTrials.gov and TTD | 7 | 5 | 5 | Drugs and targets |
| ANDECALIXIMAB | CHEMBL3833374 | Antibody | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FIDRISERTIB | CHEMBL4802133 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 1 | 1 | Drugs and targets |
| ZILURGISERTIB | CHEMBL5314579 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 1 | 1 | Drugs and targets |
| SARACATINIB | CHEMBL217092 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FIDRISERTIB SUCCINATE | CHEMBL6068391 | Small molecule | Unknown | USAN | 1 | 0 | 0 | Drugs and targets |
| ZILURGISERTIB FUMARATE | CHEMBL5314580 | Small molecule | Unknown | USAN | 1 | 0 | 0 | Drugs and targets |
Targets5
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ABL1 | Tyrosine-protein kinase ABL1 | 1 | Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| INHBA | Inhibin beta A chain | 1 | Inhibin beta A chain inhibitor | Phase 3 | https://conductscience.org/library/genes/3624 | Drugs and targets |
| MMP9 | Matrix metalloproteinase-9 | 1 | Matrix metalloproteinase 9 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/4318 | Drugs and targets |
| RARG | Retinoic acid receptor gamma | 1 | Retinoic acid receptor gamma agonist | Approval | https://conductscience.org/library/genes/5916 | Drugs and targets |
| SRC | Proto-oncogene tyrosine-protein kinase Src | 1 | Tyrosine-protein kinase SRC inhibitor | Phase 2 | https://conductscience.org/library/genes/6714 | Drugs and targets |
Trials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03312634 | An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. | Phase 3 | 107 | 2023-03-14 | Fibrodysplasia Ossificans Progressiva | PALOVAROTENE | Its record names the disease | ClinicalTrials.gov |
| NCT05027802 | A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. | Phase 3 | 61 | 2025-06-13 | Fibrodysplasia Ossificans Progressiva (FOP) | PALOVAROTENE | Its record names the disease | ClinicalTrials.gov |
| NCT03188666 | A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva | Phase 2 | 44 | 2022-12-02 | Fibrodysplasia Ossificans Progressiva | GARETOSMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02521792 | In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects | Phase 2 | 6 | 2020-10-19 | Fibrodysplasia Ossificans Progressiva | PALOVAROTENE | Its record names the disease | ClinicalTrials.gov |
| NCT05039515 | A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). | Phase 2 | 113 | Fibrodysplasia Ossificans Progressiva | FIDRISERTIB | Its record names the disease | ClinicalTrials.gov | |
| NCT05090891 | To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | Phase 2 | 98 | Fibrodysplasia Ossificans Progressiva (FOP) | ZILURGISERTIB | Its record names the disease | ClinicalTrials.gov | |
| NCT06508021 | A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) | Phase 2/3 | 92 | Fibrodysplasia Ossificans Progressiva | ANDECALIXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05394116 | A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 | 63 | Fibrodysplasia Ossificans Progressiva | GARETOSMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04307953 | Saracatinib Trial TO Prevent FOP | Phase 2 | 20 | Fibrodysplasia Ossificans Progressiva | SARACATINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT07559513 | A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 | 18 | Fibrodysplasia Ossificans Progressiva, FOP | GARETOSMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials11
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 42805227 | DERIVED | 1 | PubMed |
| 41806277 | DERIVED | 1 | PubMed |
| 41360500 | DERIVED | 1 | PubMed |
| 39381032 | DERIVED | 1 | PubMed |
| 39216107 | DERIVED | 1 | PubMed |
| 37770652 | DERIVED | 1 | PubMed |
| 37156007 | DERIVED | 1 | PubMed |
| 36583535 | DERIVED | 1 | PubMed |
| 35650602 | DERIVED | 1 | PubMed |
| 32557665 | DERIVED | 1 | PubMed |
1 to 10 of 11
See all 11 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007606
GET https://conductscience.org/api/diseases/v1/MONDO_0007606/drugs